• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Identification and clinical implication of biomarkers for mitochondrial diseases

Research Project

Project/Area Number 18K15698
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 52050:Embryonic medicine and pediatrics-related
Research InstitutionHokkaido University

Principal Investigator

Ho Hsinjung  北海道大学, 保健科学研究院, 特任講師 (50815561)

Project Period (FY) 2018-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
KeywordsMitochondria / chronic kidney disease / mitochondria / kidney / lipid / cardiolipin / mitofilin / gut microbial status / uremic toxins / SGLT1 / Mitochondrial disease / biomarker / MA-5
Outline of Final Research Achievements

For seeking a novel therapeutic approach for the treatment of mitochondria disorder, several studies have been performed. First, the function of mitofilin, which play an indispensable role in the maintenance of mitochondrial function. Second, for the reason of high mitochondrial content and oxygen consumption in the kidney, the continuous mitochondrial dysfunction plays an essential role in progression of renal diseases. Here, we also investigated a new candidate drug for chronic kidney disease and focused on the correlation between lipotoxicity and mitochondrial dysfunction in the kidney.
The current study found that a SGLT1 inhibitor decreased the accumulated uremic toxins in the renal failure mice, through altering the gut microbiota composition without changing renal function. Moreover, using a proximal tubule epithelial cell line, lipid droplets accumulated in fatty acids treated cells accompanied by decreased ATP production and mitochondrial dysfunction.

Academic Significance and Societal Importance of the Research Achievements

本研究では、腸内細菌叢の変化により腎障害の改善作用や、腎臓の近位尿細管細胞の脂肪滴の減少により、活性酸素種の消去およびミトコンドリア障害の改善作用を示した、将来的にはミトコンドリアのエネルギー代謝機構を解明することで、新たな治療戦略になり、あるいは新たなバイオマーカーを見つけることができると考え、ミトコンドリア病や腎疾患の患者の減少、医療費削減に貢献することができると考える。

Report

(3 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • Research Products

    (2 results)

All 2018

All Presentation (2 results)

  • [Presentation] SGLT1阻害による腸内細菌叢ならびに代謝物変化の解析2018

    • Author(s)
      何 欣蓉、金光 祥臣、三枝 大輔、菊地 晃一、南都 文香、三島 英換、及川 善嗣、松橋 徹郎、秋山 由雅子、鈴木 千登世、鈴木 健弘、伊藤 貞嘉、富岡 佳久、阿部 高明
    • Organizer
      Uremic toxin研究会
    • Related Report
      2018 Research-status Report
  • [Presentation] Alteration of gut microbiota by SGLT1 inhibitor may reduce uremic toxins in adenine-induced CKD mouse2018

    • Author(s)
      Hsin-Jung Ho, Yoshitomi Kanemitsu, Daisuke Saigusa, Koichi Kikuchi, Fumika Nanto, Eikan Mishima, Yoshitsugu Oikawa, Tetsuro Matsuhashi, Yukako Akiyama, Chitose Suzuki, Takehiro Suzuki, Sadayoshi Ito, Yoshihisa Tomioka and Takaaki Abe
    • Organizer
      日本腎臓学会
    • Related Report
      2018 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi